Skip to main content

PerkinElmer Value Stock - Dividend - Research Selection

Perkinelmer

ISIN: US7140461093 , WKN: 850943

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment develops and offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries; and laboratory services. In addition, this segment offers a suite of solutions comprising reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market. The Diagnostics segment provides instruments, reagents, and software test and screen products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used in diagnosing genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in applications covering oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. has a collaboration agreement with Helix. The company was founded in 1931 and is headquartered in Waltham, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


1 Healthcare Stock to Target This Week and 2 to Turn Down

2025-03-31
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 11.1%. This drop was worse than the S&P 500’s 4% decline.

Revvity Inc. stock outperforms competitors despite losses on the day

2025-03-28
Revvity Inc. stock outperforms competitors despite losses on the day

The total return for Revvity (NYSE:RVTY) investors has risen faster than earnings growth over the last five years

2025-03-25
If you buy and hold a stock for many years, you'd hope to be making a profit. But more than that, you probably want to...

Revvity Inc. stock underperforms Tuesday when compared to competitors

2025-03-25
Revvity Inc. stock underperforms Tuesday when compared to competitors

Revvity Inc. stock rises Monday, still underperforms market

2025-03-24
Revvity Inc. stock rises Monday, still underperforms market

Revvity Stock Tumbles Despite Expanding Genomics England Alliance

2025-03-21
RVTY expands its alliance with Genomics England to boost newborn genomic sequencing research, aiming to enhance early diagnosis and healthcare outcomes.

Revvity Inc. stock underperforms Thursday when compared to competitors

2025-03-20
Revvity Inc. stock underperforms Thursday when compared to competitors

Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England

2025-03-20
WALTHAM, Mass., March 20, 2025--Revvity announced an agreement with Genomics England to further collaborate on the Generation Study by providing sequencing services.

Revvity Inc. stock underperforms Wednesday when compared to competitors

2025-03-19
Revvity Inc. stock underperforms Wednesday when compared to competitors

Revvity Inc. stock outperforms competitors on strong trading day

2025-03-17
Revvity Inc. stock outperforms competitors on strong trading day